In early-stage BC, TIGIT was highly co-expressed with other immune checkpoint receptors, like PD-1, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), LAG-3, and TIM-3. This evidence concerns the gene TIGIT and breast cancer.